MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/cncr.27539

Медицинская библиотека · Cancer · 2012

Utility of serum tumor markers during surveillance for stage I seminoma.

Vesprini Danny, Chung Peter, Tolan Shaun, Gospodarowicz Mary, Jewett Michael, O'Malley Martin, Sweet Joan, Moore Malcolm, Panzarella Tony, Sturgeon Jeremy, Sugar Linda, Anson-Cartwright Lynn, Warde Padraig

Оценочное исследованиеСтатьяПеревод в очереди

Аннотация

BACKGROUND

The serum tumor markers α-fetoprotein (AFP), β-human chorionic gonadotropin (HCG), and lactate dehydrogenase (LDH) are often measured as part of surveillance protocols in patients with stage I seminoma. In this study, the authors evaluated the utility of routine measurement of these markers in the detection of disease relapse.

METHODS

Data were gathered from a prospectively maintained database of patients who underwent surveillance for stage I testicular seminoma diagnosed between 1982 and 2005 at Princess Margaret Hospital. Patients were followed on a predefined schedule with physical examination (PE), serum tumor markers, abdominopelvic computed tomography, and chest x-rays. The records of patients who relapsed were examined for details of imaging and serum tumor markers throughout the period of follow-up until the time of relapse.

RESULTS

Of the 527 patients who were managed by surveillance, 75 patients (14%) relapsed at a median follow-up of 72 months. Of these, 65 patients relapsed within the first 3 years and had routine serum tumor markers measured. In total, 11 patients had abnormal tumor markers at the time of relapse (AFP, 0 patients; HCG, 6 patients; LDH, 4 patients; and HCG and LDH, 1 patient). Only 1 patient had an elevated tumor marker (LDH) before relapse, as defined by an abnormal imaging study (n = 64) or physical examination (n = 1), for which the treatment and outcome were not affected.

CONCLUSIONS

Serum tumor marker levels did not aid in the early diagnosis of disease relapse in patients with stage I seminoma who were managed with surveillance. The current results indicated that routine measurement of serum tumor markers can be discontinued safely in seminoma surveillance schedules.

Для цитирования: Vesprini Danny, Chung Peter, Tolan Shaun, Gospodarowicz Mary, Jewett Michael, O'Malley Martin, Sweet Joan, Moore Malcolm, Panzarella Tony, Sturgeon Jeremy, Sugar Linda, Anson-Cartwright Lynn, Warde Padraig. Utility of serum tumor markers during surveillance for stage I seminoma.. Cancer. 2012. DOI: 10.1002/cncr.27539.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.